peptides
AOD-9604 10mg
AOD-9604 is a modified C-terminal fragment of human growth hormone studied for selective lipolysis and fat metabolism without effects on IGF-1 or glucose.
Research-observed benefits
- ›Selective lipolysis
- ›Fat metabolism
- ›No IGF-1 elevation
- ›Glucose-neutral
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 2 mL BAC water → 5.00 mg/mL
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
120 units
Order type
Purchase option
Quantity
Total
$80
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
AOD-9604 10mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Synthetic 15-amino-acid C-terminal fragment of human growth hormone (hGH 176-191) with a modified tyrosine residue. Activates β3-adrenergic receptors and lipolysis in adipose tissue without impacting IGF-1 or glucose homeostasis.
How It Helps
Promotes selective fat breakdown in white adipose tissue while remaining metabolically neutral — research models show fat loss without the insulin resistance or growth-related effects seen with full-length GH.
Half-Life
~2–3 hours plasma; lipolytic effects persist several hours per dose.
Onset of Effects
Changes in adipose markers within 2–4 weeks; body-composition effects compound over 8–12 weeks.
Administration
Subcutaneous injection, typically abdomen or thigh.
Storage
Lyophilized: –20°C stable 24+ months. Reconstituted: refrigerate 2–8°C, use within 28 days.
Reconstitution Guide
10 mg vial + 2 mL BAC → 5 mg/mL (0.5 mg per 0.1 mL). 1 mL BAC → 10 mg/mL for compact dosing.
Precise Dosing Protocols
Fat-loss research
- Dose:
- 300–500 mcg
- Frequency:
- Once daily SC
- Duration:
- 8–12 weeks
- Notes:
- Morning dosing aligns with fasting lipolytic windows
Higher-frequency research
- Dose:
- 300 mcg
- Frequency:
- Twice daily SC
- Duration:
- 8–12 weeks
Stacks Well With
- ›MOTS-c (mitochondrial fat oxidation)
- ›Tesamorelin (visceral fat reduction)
- ›CJC-1295/Ipamorelin (lean mass support)
Research-Observed Side Effects
- •Mild injection-site reaction
- •Transient headache
- •Occasional flushing
Translational Cautions
- •Active malignancy in translational models
- •Pregnancy in human translation studies
Cycling Guidance
8–12 weeks on, 4 weeks off to reassess adipose response.
Research Highlights
- ▸Heffernan et al. (2001): first demonstration of preserved lipolytic activity in hGH 176-191 fragment.
- ▸Franco et al. (2005): reduced fat mass without IGF-1 elevation or glucose impairment.
- ▸Widely studied in metabolic syndrome and obesity models.